JPMorgan Chase & Co. (JPM) vs Merck & Co., Inc. (MRK)

JPMorgan Chase & Co. is a leading global financial services company operating in 66 countries with more than 318,000 employees as of year-end 2025. Through its JPMorgan brands, the bank holding company reported a $4.9 trillion balance sheet and $2.68 trillion in deposits as of March 2026. Revenue is generated across three main business segments: Consumer & Community Banking, Commercial & Investment Bank, and Asset & Wealth Management. The firm holds the top global position in investment banking fees with an 8.4% market share, serves millions of customers through more than 5,000 U.S. branches, and oversees over $7.1 trillion in client assets in its wealth and asset management business.

Merck & Co., Inc. develops pharmaceutical products across multiple therapeutic areas, including cardiometabolic disorders, oncology, and infectious diseases. In cancer treatment, its immuno-oncology portfolio, led by Keytruda, represents a significant driver of total revenue. The company also maintains a strong vaccines business focused on preventing pediatric illnesses, alongside Gardasil for human papillomavirus. In addition, Merck markets animal health products. Geographically, 47% of the company’s sales come from its U.S. human health segment, which includes pharmaceuticals and vaccines.